Breast Cancer

Phase I trial results demonstrate that abemaciclib, a CDK 4/6 inhibitor, had significant clinical activity and an overall response rate of 31% in patients with hormone receptor-positive breast cancer.

Frontline treatment with fulvestrant improved progression-free survival versus anastrozole for postmenopausal patients with locally-advanced or metastatic HR-positive breast cancer.

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.

Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.

A 5-year follow-up of the phase II NeoSphere trial confirmed that patients with HER2-positive breast cancer receiving a 3-drug neoadjuvant pertuzumab regimen had better outcomes compared with patients receiving trastuzumab and docetaxel.

The combination of the CDK4/6 inhibitor ribociclib and letrozole significantly improved progression-free survival compared with letrozole alone for patients with HR-positive, HER2-negative advanced breast cancer.

Monica Arnedos, MD, assistant professor, Department of Medical Oncology, Institut de Cancérologie Gustave Roussy, discusses the Preoperative Palbociclib (POP) Randomized Trial for early-stage breast cancer.

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival for the frontline combination of palbociclib and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.

Early intervention has increasingly become the new standard of care for many patients with breast cancer, with an ever-growing collection of phase III trials currently exploring several novel or improved approaches.

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.